Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APP13007 for inflammation and pain after cataract surgery
NCT04810962Phase 3Completed
- Sponsor
- Formosa Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Nanoparticles, Implantable Devices, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 3 trial of GPN00833 in ocular inflammation, sponsored by Formosa Pharmaceuticals. Started Mar 2021; status: completed.
02
Drugs
GPN00833
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT04810962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810962.